Sanjiv Shah
0000-0002-5655-8201
27 papers found
Refreshing results…
Heart failure with preserved ejection fraction
Association of Cardiovascular Fibrosis, Remodeling, and Dysfunction With Frailty, Prefrailty, and Functional Performance: The Multi-Ethnic Study of Atherosclerosis
Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA‐HF Trials
Eicosanoid and eicosanoid-related inflammatory mediators and exercise intolerance in heart failure with preserved ejection fraction
Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?
Left Atrial Function and Arrhythmias in Relation to Small Vessel Disease on Brain MRI: The Multi‐Ethnic Study of Atherosclerosis
Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction
Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
Distribution of 10- and 30-Year Predicted Risks for Heart Failure in the US Population: National Health and Nutrition Examination Surveys 2015 to 2018
Development and Validation of a Long-Term Incident Heart Failure Risk Model
Risk-Based Intensive Blood Pressure Lowering and Prevention of Heart Failure: A SPRINT Post Hoc Analysis
Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial
Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction
Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction
Association of immune cell subsets with cardiac mechanics in the Multi-Ethnic Study of Atherosclerosis
Antihypertensive Class and Cardiovascular Outcomes in Patients With HIV and Hypertension
Association Between Myocardial Strain and Frailty in CHS
Missing publications? Search for publications with a matching author name.